Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8120553rdf:typepubmed:Citationlld:pubmed
pubmed-article:8120553lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:8120553lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:8120553lifeskim:mentionsumls-concept:C0146224lld:lifeskim
pubmed-article:8120553lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:8120553lifeskim:mentionsumls-concept:C0574032lld:lifeskim
pubmed-article:8120553lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:8120553lifeskim:mentionsumls-concept:C0040808lld:lifeskim
pubmed-article:8120553lifeskim:mentionsumls-concept:C0920321lld:lifeskim
pubmed-article:8120553pubmed:issue3lld:pubmed
pubmed-article:8120553pubmed:dateCreated1994-4-4lld:pubmed
pubmed-article:8120553pubmed:abstractTextThe objective of this trial was to define the maximum-tolerated dose (MTD) of topotecan for a 21-day infusion schedule, repeated every 28 days, in patients with cancer.lld:pubmed
pubmed-article:8120553pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8120553pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8120553pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8120553pubmed:languageenglld:pubmed
pubmed-article:8120553pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8120553pubmed:citationSubsetIMlld:pubmed
pubmed-article:8120553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8120553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8120553pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8120553pubmed:statusMEDLINElld:pubmed
pubmed-article:8120553pubmed:monthMarlld:pubmed
pubmed-article:8120553pubmed:issn0732-183Xlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:SpeyerJJlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:RaphaelBBlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:LiebelEElld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:SoriceGGlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:WernsSSlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:HochsterHHlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:OratzRRlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:TauberMMlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:ChachouaAAlld:pubmed
pubmed-article:8120553pubmed:authorpubmed-author:VinciR ZRZlld:pubmed
pubmed-article:8120553pubmed:issnTypePrintlld:pubmed
pubmed-article:8120553pubmed:volume12lld:pubmed
pubmed-article:8120553pubmed:ownerNLMlld:pubmed
pubmed-article:8120553pubmed:authorsCompleteNlld:pubmed
pubmed-article:8120553pubmed:pagination553-9lld:pubmed
pubmed-article:8120553pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:meshHeadingpubmed-meshheading:8120553-...lld:pubmed
pubmed-article:8120553pubmed:year1994lld:pubmed
pubmed-article:8120553pubmed:articleTitlePhase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen.lld:pubmed
pubmed-article:8120553pubmed:affiliationKaplan Comprehensive Cancer Center, Division of Medical Oncology, New York University Medical Center, New York 10016.lld:pubmed
pubmed-article:8120553pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8120553pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:8120553pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8120553pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8120553lld:pubmed